Kyntra Bio: Anemia trials

The registry lists 21 Anemia studies with Kyntra Bio as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 2 9Phase 3 12Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)Not yet recruitingNCT07722988Phase 3
• Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis ParticipantsCompletedNCT04484857Phase 3Results posted
• Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis ParticipantsCompletedNCT04410198Phase 3Results posted
• Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaCompletedNCT04076943Phase 2Results posted
• Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenTerminatedNCT03263091Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisCompletedNCT02273726Phase 3Results posted
• Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis ParticipantsCompletedNCT02052310Phase 3Results posted
• A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving DialysisCompletedNCT01750190Phase 3Results posted
• Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney DiseaseCompletedNCT01630889Phase 2Results posted
• Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent TreatmentCompletedNCT01414075Phase 2Results posted
• Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With AnemiaCompletedNCT01244763Phase 2Results posted
• Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisCompletedNCT01147666Phase 2Results posted
• Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring DialysisCompletedNCT00761657Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid MalignanciesCompletedNCT05301517Phase 3
• Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKDWithdrawnNCT04621331Phase 3
• Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney DiseaseCompletedNCT04059913Phase 4
• Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)CompletedNCT03303066Phase 2/3
• FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on DialysisCompletedNCT02652819Phase 3
• FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney DiseaseCompletedNCT02652806Phase 3
• Study of FG-4592 in Subjects With Chronic Kidney Disease in ChinaCompletedNCT01599507Phase 2
• A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human ErythropoietinCompletedNCT00456053Phase 2